US2020031903A1PendingUtilityA1

Activin-actrii antagonists and uses for increasing red blood cell levels

66
Assignee: ACCELERON PHARMA INCPriority: Dec 18, 2006Filed: Jan 4, 2019Published: Jan 30, 2020
Est. expiryDec 18, 2026(~0.4 yrs left)· nominal 20-yr term from priority
Inventors:Matthew L. Sherman
A61P 7/00A61P 35/00A61P 7/06A61P 43/00A61P 13/12C07K 2319/31C07K 14/71G01N 2500/04A61K 38/16A61K 38/00A61K 38/1796G01N 33/5088A61K 38/17C07K 2319/30A61K 39/395A61K 38/38G01N 33/80C07K 19/00C07K 14/475A61K 38/18
66
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.

Claims

exact text as granted — not AI-modified
1 - 20 . (canceled) 
     
     
         21 . A method of identifying an agent that increases red blood cell levels, the method comprising:
 a) identifying a test agent that binds to a ligand-binding domain of an ActRII polypeptide competitively with an ActRII ligand; and   b) evaluating the effect of the agent on red blood cell levels in an animal.   
     
     
         22 . The method of  claim 21 , wherein the agent is selected from the group consisting of non-peptidyl organic molecules, peptides, polypeptides, peptidomimetics, sugars, hormones, and nucleic acid molecules. 
     
     
         23 . The method of  claim 21 , wherein the agent is identified by a biochemical method. 
     
     
         24 . The method of  claim 21 , wherein the agent is identified by a mechanism based assay. 
     
     
         25 . The method of  claim 21 , wherein the agent is evaluated in a cell based assay. 
     
     
         26 . The method of  claim 21 , wherein the agent is evaluated in an in vivo assay. 
     
     
         27 . The method of  claim 21 , wherein the agent is evaluated in an in vitro assay. 
     
     
         28 . The method of  claim 21 , wherein the ActRII polypeptide comprises the amino acid sequence of SEQ ID NO: 2. 
     
     
         29 . The method of  claim 21 , wherein the ActRII polypeptide comprises the amino acid sequence of SEQ ID NO: 3. 
     
     
         30 . The method of  claim 21 , wherein the ActRII polypeptide comprises the amino acid sequence of SEQ ID NO: 7. 
     
     
         31 . The method of  claim 21 , wherein the ActRII polypeptide comprises the amino acid sequence of SEQ ID NO: 12. 
     
     
         32 . The method of  claim 21 , wherein the ActRII polypeptide consists of the amino acid sequence of SEQ ID NO: 7.

Join the waitlist — get patent alerts

Track US2020031903A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.